相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Treatment with Interferon alpha prior to discontinuation of Imatinib in patients with chronic myeloid leukemia
Izhar Hardan et al.
CYTOKINE (2012)
Clinical reagents of GM-CSF and IFN-α induce the generation of functional chronic myeloid leukemia dendritic cells in vitro
Kaizhi Weng et al.
CYTOTECHNOLOGY (2012)
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia
Naoto Takahashi et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa
Hidehiro Itonaga et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2012)
Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
David Marin et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
B. Hanfstein et al.
LEUKEMIA (2012)
Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias
Jorge E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV
Alice Fabarius et al.
BLOOD (2011)
Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor
Sabyasachi Bhattacharya et al.
BLOOD (2011)
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia
Bengt Simonsson et al.
BLOOD (2011)
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score
Joerg Hasford et al.
BLOOD (2011)
Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease
Jean-Claude Chomel et al.
BLOOD (2011)
The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
Elias Jabbour et al.
BLOOD (2011)
Immune Modulation of Minimal Residual Disease in Early Chronic Phase Chronic Myelogenous Leukemia A Randomized Trial of Frontline High-Dose Imatinib Mesylate With or Without Pegylated Interferon Alpha-2b and Granulocyte-Macrophage Colony-Stimulating Factor
Jorge Cortes et al.
CANCER (2011)
Dasatinib Combined with Interferon-alfa Induces a Complete Cytogenetic Response and Major Molecular Response in a Patient with Chronic Myelogenous Leukemia Harboring the T315I BCR-ABL1 Mutation
A. Megan Cornelison et al.
Clinical Lymphoma Myeloma & Leukemia (2011)
Current status of agents active against the T315I chronic myeloid leukemia phenotype
Aine Carol Burke et al.
EXPERT OPINION ON EMERGING DRUGS (2011)
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
Amie S. Corbin et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
Ruediger Hehlmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
Timothy P. Hughes et al.
BLOOD (2010)
The response to imatinib and interferon-α is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase
Francesca Palandri et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia
Andreas Burchert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
D. M. Ross et al.
LEUKEMIA (2010)
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia.
Claude Preudhomme et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
PR1-Specific T Cells Are Associated with Unmaintained Cytogenetic Remission of Chronic Myelogenous Leukemia After Interferon Withdrawal
Shreya Kanodia et al.
PLOS ONE (2010)
High rates of durable response are achieved with imatinib after treatment with interferon α plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial
Francois Guilhot et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Harmonization of molecular monitoring of CML therapy in Europe
M. C. Mueller et al.
LEUKEMIA (2009)
IFNα activates dormant haematopoietic stem cells in vivo
Marieke A. G. Essers et al.
NATURE (2009)
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-α: 5-year outcome
Francesca Palandri et al.
HAEMATOLOGICA (2008)
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate
Giuliana Alimena et al.
LEUKEMIA RESEARCH (2008)
Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-α
Susan Branford et al.
CANCER (2007)
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia
Ruediger Hehlmann et al.
BLOOD (2007)
Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys (R)) versus interferon alpha-2a (Roferon (R)-A) in patients with treatment-naive, chronic-phase chronic myelogenous leukemia
Jeffrey H. Lipton et al.
LEUKEMIA & LYMPHOMA (2007)
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
Philippe Rousselot et al.
BLOOD (2007)
Survival benefit with imatinib mesylate versus interferon-α-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia
Hagop M. Kantarjian et al.
BLOOD (2006)
Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia:: historical comparison between two phase 3 trials
Lydia Roy et al.
BLOOD (2006)
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction
Mhairi Copland et al.
BLOOD (2006)
Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-α-2a with and without cytarabine in patients with chronic myelogenous leukemia
M Talpaz et al.
CLINICAL CANCER RESEARCH (2005)
Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors
GR Angstreich et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
M Deininger et al.
BLOOD (2005)
Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study
M Michallet et al.
LEUKEMIA (2004)
To the editor: Discontinuation of imatinib therapy after achieving a molecular response
J Cortes et al.
BLOOD (2004)
Imatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia
M Baccarani et al.
BLOOD (2004)
Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups
HC Kluin-Nelemans et al.
BLOOD (2004)
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase - Comparison with historic data
HM Kantarjian et al.
CANCER (2003)
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
TP Hughes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II):: prolongation of survival by the combination of interferon α and hydroxyurea
R Hehlmann et al.
LEUKEMIA (2003)
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment
R Bhatia et al.
BLOOD (2003)
Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis
M Chawla-Sarkar et al.
APOPTOSIS (2003)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Complete cytogenetic and molecular responses to interferon-α-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis
HM Kantarjian et al.
CANCER (2003)
Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia
A Burchert et al.
BLOOD (2003)
Interferon-α induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo
RL Paquette et al.
LEUKEMIA (2002)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
H Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa
FX Mahon et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
SM Graham et al.
BLOOD (2002)
A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia
M Baccarani et al.
BLOOD (2002)
Chronic myeloid leukemia and interferon-α:: a study of complete cytogenetic responders
F Bonifazi et al.
BLOOD (2001)
Phase 1 study of polyethylene glycol formulation of interferon α-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia
M Talpaz et al.
BLOOD (2001)
The p38 MAPK pathway mediates the growth inhibitory effects of interferon-α in BCR-ABL-expressing cells
IA Mayer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities
E Jonasch et al.
ONCOLOGIST (2001)
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
JJ Molldrem et al.
NATURE MEDICINE (2000)
分享论文
